Vertex Pharmaceuticals Incorpor (VRTX) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Wait for pullback to $437.11. At $452.33 the A.R:R is 1.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $437.11 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CF medicines; Thin upside margin: 9.2%.
Vertex Pharmaceuticals is a global biotechnology company with approved medicines for cystic fibrosis (its CFTR modulators such as TRIKAFTA and ALYFTREK), sickle cell disease and transfusion-dependent beta thalassemia (the CRISPR gene-editing therapy CASGEVY), and acute pain... Read more
Wait for pullback to $437.11. At $452.33 the A.R:R is 1.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $437.11 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CF medicines; Thin upside margin: 9.2%. Chart setup: Trend continuation, RSI 59, MACD bullish. Wide-moat business. Accumulate on weakness. Score 6.1/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Vertex Pharmaceuticals Incorpor
About Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals commercializes five approved CF medicines — ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO — used by nearly three-quarters of approximately 97,000 people with cystic fibrosis in the U.S., Europe, Australia, and Canada, with an estimated 112,000 people with CF across all target markets. The portfolio also includes CASGEVY, a CRISPR/Cas9 gene-editing therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX, a selective NaV1.8 acute-pain inhibitor approved by the FDA in January 2025.
The company sells primarily to a limited number of specialty pharmacy and specialty distributors globally, plus certain major U.S. wholesalers, with U.S. customers reselling to patients, healthcare providers, retail pharmacies, hospitals, or authorized treatment centers; ex-U.S. distribution runs through distributor arrangements, retail pharmacies, hospitals, and clinics, many government-owned. CF medicines dominate the revenue base — the 10-K states substantially all net product revenues have been derived from CF — with the medicines reimbursed or accessible in more than 60 countries across six continents. CASGEVY uses a multi-step ex-vivo manufacturing chain anchored on authorized treatment centers; 64 patients received infusions globally in 2025 and 147 had first cell collections. JOURNAVX recorded more than 550,000 prescriptions filled between U.S. launch in March 2025 and year-end 2025, with coverage extended to more than 200 million commercial and government lives plus Medicaid coverage in 21 states. The mid- and late-stage pipeline spans povetacicept (IgA nephropathy, primary membranous nephropathy), inaxaplin (APOL1-mediated kidney disease), suzetrigine (diabetic peripheral neuropathy), and zimislecel (type 1 diabetes).
Show full overview
Pricing-power transition is the dominant near-term policy lens for Vertex. The 10-K notes Colorado's Prescription Drug Affordability Board selected TRIKAFTA for an affordability review in August 2023; while it was later found ineligible for an upper payment limit, the company cannot predict whether future PDAB reviews will reach the same conclusion. The filing separately flags CMS's recently proposed GUARD Model imposing most-favored-nation pricing on U.S. prescription drug prices in government programs, alongside Inflation Reduction Act-driven Medicare negotiation pressure and march-in rights. In December 2024, the FDA required moving TRIKAFTA liver-injury information into a boxed warning, with similar language imposed on the ALYFTREK label — a safety label change that may impact acceptance if competing CFTR modulators emerge.
See also: Healthcare · Biotechnology
From Vertex Pharmaceuticals Incorpor's most recent 10-K filing, extracted May 16, 2026.
Recent developments
updated 2026-06-15Recent Developments — Vertex Pharmaceuticals Incorpor
Latest news
- NEWS Why Vertex Pharmaceuticals Stock Looks Undervalued in 2026 - TIKR.com — TIKR.com positive
- NEWS Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs - TradingView — TradingView neutral
- NEWS Truist assumes Vertex stock coverage with buy rating on kidney drugs By Investing.com - Investing.com India — Investing.com India positive
- NEWS Truist assumes Vertex stock coverage with buy rating on kidney drugs - Investing.com Nigeria — Investing.com Nigeria positive
- NEWS Vertex Pharmaceuticals Incorporated (VRTX) Latest Stock News & Headlines - Yahoo Finance — Yahoo Finance neutral
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCF medicines10-K Item 1A: 'Substantially all our net product revenues have been derived from the sale of our CF medicines.'
- MEDIUMCustomerlimited number of specialty pharmacy and specialty distributors10-K Item 1: 'We sell our medicines primarily to a limited number of specialty pharmacy and specialty distributors globally, as well as to certain major wholesalers in the U.S.'
Material Events(8-K, last 90d)
- 2026-04-29Item 5.02MEDIUMDirector Suketu Upadhyay informed the Board on April 28, 2026 he will not stand for re-election at the 2026 annual meeting, having been named forthcoming CFO of Incyte Corporation; decision cited scheduling conflicts with no disagreement on operations, policies or practices. Board intends to reduce to ten members.SEC filing →
- 2026-05-13Item 5.02LOWOn March 27, 2026 the Board approved the Vertex 2026 Stock and Option Plan, replacing the 2013 Stock and Option Plan, subject to shareholder approval; the plan was approved by shareholders at the May 13, 2026 annual meeting. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $437.11. At $452.33 the A.R:R is 1.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $437.11 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CF medicines; Thin upside margin: 9.2%. Chart setup: Trend continuation, RSI 59, MACD bullish. Wide-moat business. Accumulate on weakness. Target $493.82 (+9.2%), stop $413.87 (−9.3%), Setup A.R:R 2.3:1. Score 6.1/10, moderate confidence.
Take-profit target: $493.82 (+12.1% upside). Target $493.82 (+9.2%), stop $413.87 (−9.3%), Setup A.R:R 2.3:1. Stop-loss: $413.87.
Concentration risk — Product: CF medicines; Thin upside margin: 9.2%.
Vertex Pharmaceuticals Incorpor trades at a P/E of 26.4 (forward 20.7). TrendMatrix value score: 4.6/10. Verdict: Buy (Wait for Entry).
40 analysts cover VRTX with a consensus score of 4.1/5. Average price target: $549.
What does Vertex Pharmaceuticals Incorpor do?Vertex Pharmaceuticals is a global biotechnology company with approved medicines for cystic fibrosis (its CFTR...
Vertex Pharmaceuticals is a global biotechnology company with approved medicines for cystic fibrosis (its CFTR modulators such as TRIKAFTA and ALYFTREK), sickle cell disease and transfusion-dependent beta thalassemia (the CRISPR gene-editing therapy CASGEVY), and acute pain (JOURNAVX). Substantially all of its net product revenues come from its CF medicines, which are used by nearly three quarters of the roughly 97,000 people with CF across the U.S., Europe, Australia and Canada. It sells primarily to a limited number of specialty pharmacies, specialty distributors and major U.S. wholesalers,